Home LiteratureArticle Details
PMID: 20071572 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Journal of virology ·Vol. 84 ·No. 7 ·2010-04-00 ·Pages 3201-9

Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J

Abstract

The recent outbreaks of influenza A H5N1 virus in birds and humans have necessitated the development of potent H5N1 vaccines. In this study, we evaluated the protective potential of an immediate-early promoter-based baculovirus displaying hemagglutinin (BacHA) against highly pathogenic avian influenza (HPAI) H5N1 virus infection in a mouse model. Gastrointestinal delivery of BacHA significantly enhanced the systemic immune response in terms of HA-specific serum IgG and hemagglutination inhibition (HI) titers. In addition, BacHA vaccine was able to significantly enhance the mucosal IgA level. The inclusion of recombinant cholera toxin B subunit as a mucosal adjuvant along with BacHA vaccine did not influence either the systemic or mucosal immunity. Interestingly, an inactivated form of BacHA was able to induce only a negligible level of immune responses compared to its live counterpart. Microneutralization assay also indicated that live BacHA vaccine was able to induce strong cross-clade neutralization against heterologous H5N1 strains (clade 1.0, clade 2.1, and clade 8.0) compared to the inactivated BacHA. Viral challenge studies showed that live BacHA was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1. Moreover, histopathological examinations revealed that mice vaccinated with live BacHA had only minimal bronchitis in lungs and regained their body weight more rapidly postchallenge. Furthermore, immunohistochemistry results demonstrated that the live BacHA was able to transduce and express HA in the intestinal epithelial cells in vitro and in vivo. We have demonstrated that recombinant baculovirus with a white spot syndrome virus (WSSV) immediate-early promoter 1 (ie1) acted as a vector as well as a protein vaccine and will enable the rapid production of prepandemic and pandemic vaccines without any biosafety concerns.

MeSH Terms
Animals Antibodies, Viral/blood Baculoviridae/genetics Female HCT116 Cells Hemagglutinin Glycoproteins, Influenza Virus/chemistry,genetics,immunology Humans Immunoglobulin G/blood Influenza A Virus, H5N1 Subtype Influenza Vaccines/immunology Intestinal Mucosa/immunology Mice Mice, Inbred BALB C Orthomyxoviridae Infections/prevention & control Spodoptera Vaccination Vaccines, Synthetic/immunology
Chemicals
Antibodies, Viral Hemagglutinin Glycoproteins, Influenza Virus Immunoglobulin G Influenza Vaccines Vaccines, Synthetic
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Prabakaran Mookkan
Animal Health Biotechnology, Temasek Life Science Laboratory, 1 Research Link, National University of Singapore, Singapore 117604.
Madhan Selvaraj
Prabhu Nayana
Qiang Jia
Kwang Jimmy
References (32)
32 references, click to expand
  1. Vaccination strategies for mucosal immune responses.
    Clin Microbiol Rev. 2001 Apr;14(2):430-45 PMID: 11292646
  2. Recombinant baculoviruses as mammalian cell gene-delivery vectors.
    Trends Biotechnol. 2002 Apr;20(4):173-80 PMID: 11906750
  3. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses.
    PLoS One. 2009;4(2):e4566 PMID: 19238211
  4. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus.
    Science. 2004 Mar 19;303(5665):1866-70 PMID: 14764887
  5. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.
    JAMA. 2007 Apr 11;297(14):1577-82 PMID: 17426277
  6. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice.
    J Immunol. 2003 Aug 1;171(3):1133-9 PMID: 12874198
  7. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep. 2004 May 28;53(RR-6):1-40 PMID: 15163927
  8. Evolution of H5N1 avian influenza viruses in Asia.
    Emerg Infect Dis. 2005 Oct;11(10):1515-21 PMID: 16318689
  9. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes.
    J Vet Med Sci. 1998 Sep;60(9):1047-50 PMID: 9795911
  10. Baculovirus vector as a delivery vehicle for influenza vaccines.
    Expert Rev Vaccines. 2009 Apr;8(4):455-67 PMID: 19348561
  11. The potential use of receptor-mediated endocytosis for oral drug delivery.
    Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):59-73 PMID: 11259833
  12. Baculoviral display of the green fluorescent protein and rubella virus envelope proteins.
    Biochem Biophys Res Commun. 1997 Sep 29;238(3):717-22 PMID: 9325155
  13. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens.
    Vaccine. 1991 May;9(5):303-8 PMID: 1651609
  14. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.
    JAMA. 2006 Feb 22;295(8):891-4 PMID: 16456087
  15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Virology. 2008 Oct 25;380(2):412-20 PMID: 18786689
  16. Baculovirus stimulates antiviral effects in mammalian cells.
    J Virol. 1999 Dec;73(12):9944-51 PMID: 10559307
  17. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin.
    Vaccine. 2004 Jun 23;22(19):2425-9 PMID: 15193405
  18. A chimeric baculovirus displaying bovine herpesvirus-1 (BHV-1) glycoprotein D on its surface and their immunological properties.
    Appl Microbiol Biotechnol. 2007 May;75(2):407-14 PMID: 17285288
  19. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.
    Vaccine. 2001 Feb 8;19(13-14):1732-7 PMID: 11166898
  20. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    J Virol. 2007 Apr;81(7):3514-24 PMID: 17251294
  21. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.
    J Virol. 2008 Jul;82(13):6200-8 PMID: 18417563
  22. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    PLoS Med. 2006 Sep;3(9):e360 PMID: 16968127
  23. Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens.
    Clin Diagn Lab Immunol. 1994 Mar;1(2):150-4 PMID: 7496936
  24. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN.
    J Immunol. 2007 Feb 15;178(4):2361-9 PMID: 17277142
  25. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles.
    Vaccine. 2000 Nov 22;19(7-8):726-34 PMID: 11115693
  26. Baculovirus is an efficient vector for the transduction of the eye: comparison of baculovirus- and adenovirus-mediated intravitreal vascular endothelial growth factor D gene transfer in the rabbit eye.
    J Gene Med. 2009 May;11(5):382-9 PMID: 19263462
  27. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    J Infect Dis. 2006 Nov 15;194(10):1394-7 PMID: 17054068
  28. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.
    J Virol. 2008 Mar;82(5):2486-92 PMID: 18160446
  29. In vitro and in vivo gene delivery by recombinant baculoviruses.
    J Virol. 2003 Sep;77(18):9799-808 PMID: 12941888
  30. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
    Eur J Immunol. 1984 Apr;14(4):350-6 PMID: 6609824
  31. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.
    PLoS One. 2008 Jan 30;3(1):e1501 PMID: 18231588
  32. Assembly of influenza hemagglutinin trimers and its role in intracellular transport.
    J Cell Biol. 1986 Oct;103(4):1179-91 PMID: 2429970
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
DOI
10.1128/JVI.02175-09
Published
2010-04-00
Epub
2010-00-13
Pages
3201-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2838147
Subset
IM
External Links
PubMed source DOI: 10.1128/JVI.02175-09 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2